Gómez-Muñoz, F. (Fernando)

Filtering

20201

Settings

Author search.filters.isAuthorOfPublication.8171f933-d2e9-4f77-ac41-d98f59c7db99

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice
    (2020) Habert, P. (Paul); Gaubert, J.Y. (Jean-Yves); Klompenhouwer, L.G. (Lisa G.); Gómez-Muñoz, F. (Fernando); Vilares-Morgado, P. (Paulo); Bilbao, J.I. (José I.); Maas, M. (Monique); Cornelis, F.H. (Francois H.); Beets-Tan, R. (Regina); Schaefer, N. (Niklaus); Solomon, S.B. (Stephen B.); van-der-Reijd, D. (Denise)
    Interventional radiology plays an important and increasing role in cancer treatment. Follow-up is important to be able to assess treatment success and detect locoregional and distant recurrence and recommendations for follow-up are needed. At ECIO 2018, a joint ECIO-ESOI session was organized to establish follow-up recommendations for oncologic intervention in liver, renal, and lung cancer. Treatments included thermal ablation, TACE, and TARE. In total five topics were evaluated: ablation in colorectal liver metastases (CRLM), TARE in CRLM, TACE and TARE in HCC, ablation in renal cancer, and ablation in lung cancer. Evaluated modalities were FDG-PET-CT, CT, MRI, and (contrast-enhanced) ultrasound. Prior to the session, five experts were selected and performed a systematic review and presented statements, which were voted on in a telephone conference prior to the meeting by all panelists. These statements were presented and discussed at the ECIO-ESOI session at ECIO 2018. This paper presents the recommendations that followed from these initiatives. Based on expert opinions and the available evidence, follow-up schedules were proposed for liver cancer, renal cancer, and lung cancer. FDG-PET-CT, CT, and MRI are the recommended modalities, but one should beware of false-positive signs of residual tumor or recurrence due to inflammation early after the intervention. There is a need for prospective preferably multicenter studies to validate new techniques and new response criteria. This paper presents recommendations that can be used in clinical practice to perform the follow-up of patients with liver, lung, and renal cancer who were treated with interventional locoregional therapies.